Advaxis, Inc. is a biotechnology company that uses a bioengineered bacterium, Listeria monocytogenes to activate the immune system to treat cancer, infectious disease or allergic syndromes. Based upon more than 20 years of discovery by Yvonne Paterson, Ph.D., Professor of Microbiology at the University of Pennsylvania, it has been found that this unique microbe is capable of stimulating numerous aspects of the immune system simultaneously; including, strongly stimulating innate immunity and both arms of the cellular adaptive immune response, stimulating non-classical immune mechanisms in the blood and bone marrow, and altering tumor microenvironments to allow the immune response to work. This unique approach has resulted in extremely effective agents for the treatment of existing cancers and other diseases. Unlike other therapeutic approaches, in pre-clinical research Advaxis’ Listeria technology has been able to consistently demonstrate complete therapeutic responses resulting in complete tumor regression. Preliminary results in humans have shown this technology to be safe, and the therapeutic outcomes are very encouraging. |
For further information visit Advaxis website. Current PPS: 0.185 O/S: 116M Advaxis blog: link * We have no association with Advaxis or it's associates. We intend to bring some of the brightest companies to our readers. Use this blog as a starting point for your research and invest at your own risk. |
No comments:
Post a Comment